Neurodegeneration – Webinars and Online Events

This event will cover innovations in advanced in vitro and in vivo disease modeling and how these advancements are accelerating drug discovery, personalized medicine and our understanding of complex disease mechanisms.

This webinar explores the precision and correlation of leading large-scale proteomic platforms, providing essential insights for human plasma proteome profiling.

Improved sensitivity in proteomics analysis has numerous benefits including bringing down the sample requirements for analysis and thus facilitates a wide range of applications in drug discovery that were previously not feasible before.

The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating disease mechanisms.

Recent technological progress has allowed biologists to measure an unprecedented number of these molecules throughout an organism, providing unique insights into the physiological and pathological conditions of cells and organs, including the aging

MALDI mass spectrometry imaging has emerged as a powerful technology platform for spatially resolved analysis and visualization of a wide range of molecules – including drugs, metabolites, peptides and more – in pharmaceutical R&D, clinical research and basic science. Advances in MALDI workflows are making the technique more accessible.
In this webinar, our speaker will discuss how a new MALDI workflow can be used to analyze lipids in degenerative disease and Alzheimer’s models, contextualizing lipid distribution by enabling comparison to multiple protein markers.
He’ll also highlight how the new workflow can be applied to the study of tumor subtypes and the tumor microenvironment.

In this webinar, we’ll explore how integrating proteomics with systems biology sheds light on the complexities of AD pathology.

This webinar explores a highly sensitive, automated assay workflow to provide high-quality results for low-abundance biomarkers in serum, plasma and cerebrospinal fluid.

Explore the tools and techniques being used to study diseases in the lab. Discover how advances in cell culture and disease modeling are supporting diagnostic and therapeutic development.

Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. While several peptide and protein biomarkers in cerebrospinal fluid (CSF) have been used for AD diagnosis, an unequivocal diagnosis in the early phases of AD is still lacking.